2026 BSR Guideline for the Treatment of Polymyalgia Rheumatica Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. https://t.co/o1Y1a13WIG https://t.co/W9jNGfMgP7

Boston study of 25 systemic sclerosis pts has shown spatial frequency domain imaging (SFDI) is a noninvasive evaluation of skin, but only has weak-to-moderate correlation w/ mRSS (r −0.38 to −0.48); somewhat better w/ histology/fibrosis (r −0.35 to −0.52) https://t.co/N1uSWjNEcl

2024 web survey of German rheumatologists on CAR-T & T-cell redirecting therapies. 95% willing to refer pts to specialized centers; but 5% (most severe) are suitable for TCRT. Barriers cited: high costs (82%), limited experience (65%) & limited # appropriate Pts (35%). 4.86/10 https://t.co/o62uRVsIC7

Artiva has stopped development of its AlloNK (allogeneic NK cell therapy) after 2 reported deaths in their phase II RCT in #RA and other autoimmune conditions. Artiva has suspended its phase III trial with AlloNK. https://t.co/mLR6xciRfB https://t.co/mv2m8rhst6

Mark your calendar: RheumNow is covering ACR Convergence 2026, beginning November 7th! Follow along for clinical trial highlights, expert perspectives, daily faculty recaps, livestreams and more. Visit https://t.co/ofGKCCNQnE for the latest coverage. #ACR26 #Rheumatology https://t.co/5p5UxMLu51

Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/ZumTjOcrEa

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. https://t.co/J1EQHGzR5O https://t.co/w3rQ3AbrYt

Medicaid adults w/ new low back pain Rx w/ higher-dose opioids have a 2.5 fold risk of later opioid use disorder or overdose. Retro study of ~400K opioid naive LBP pts https://t.co/9CTqaQ17vz https://t.co/hCY9KwCqLx

CLARITY-1 & CLARITY-2 Phase 3 Trials show Brepocitinib effective in Non-Infectious Uveitis. 371 pts Rx w. brepocitinib 45 mg or placebo x48wks w/ 2 wks of Pred taper. Time to Rx failure greater w/ BREP (48 vs 12 wks PBO; p<0.0001)https://t.co/EBaWe7TJbt https://t.co/UVg188eEHZ

Beverages & relative risk of hyperuricemia (HUA) & gout. Metanalysis of 52 studies shows alcohol has signif high risk of gout (OR  1.8) & HUA (OR 1.5); & sugar-sweetened beverages (SSBs) incr gout (1.37) & HUA (1.48); as well as tea for HUA among female (OR = 1.29). Coffee https://t.co/nq1fKvOlgv

High TB & LTBI burden in Latin America. Review of PANLAR registry 590 IMID pts (54% GC, 44% bDMARDs (TNFi), 29% JAKi, 27% csDMARD). Only 430 (73%) had TB screening- 59 (14%) Dx w/ LTBI. @12 mos, 99 repeat TB screening - 5 new LTBI cases Dx. Only 2 (0.34%) had active TB. (CDC https://t.co/wnPdEueb4N

Rheum Survey on SCLE> In your clinic, what is the most common cause of drug-induced subacute cutaneous lupus (SCLE). CLICK HERE>> https://t.co/LdnYIw0Qw3 https://t.co/qWUqwFpLta

Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/KtH0AIatdq

Two crystals in one joint? Cryptococcus risk doubled with JAK inhibitors? And early damage in Sjögren’s linked to a 12–14-fold increase in lymphoma risk? Dr. Jack Cush breaks down the findings behind the numbers in this week's RheumNow roundup: - JAK inhibitors: Cryptococcal https://t.co/4RkznhyoIt

TENS does NOT work in knee OA (KOA). Sham controlled RCT of 96 KOA pts (all Rx w/ exercise) randomized to TENS or sham show no betw group difference in KOOS score at 1 mo, nor did they achieve the minimal clinically important difference. https://t.co/1xPtNn7MM0 https://t.co/GLCfzWP39D